Cencora, Inc. Files Definitive Proxy Statement for 2024 Annual Meeting

Ticker: COR · Form: DEF 14A · Filed: Jan 29, 2024 · CIK: 1140859

Cencora, INC. DEF 14A Filing Summary
FieldDetail
CompanyCencora, INC. (COR)
Form TypeDEF 14A
Filed DateJan 29, 2024
Risk Levelmedium
Pages14
Reading Time17 min
Key Dollar Amounts$262.2B, $3.3B, $3.1B, $11.99, $12 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: Cencora, Proxy Statement, PharmaLex Acquisition, OneOncology Investment, Board Succession

TL;DR

<b>Cencora, Inc. (formerly AmerisourceBergen) filed its Definitive Proxy Statement, highlighting strategic acquisitions like PharmaLex and OneOncology, board succession, and a rebranding initiative.</b>

AI Summary

Cencora, Inc. (COR) filed a Proxy Statement (DEF 14A) with the SEC on January 29, 2024. Cencora, formerly AmerisourceBergen, rebranded in fiscal 2023 to reflect its global evolution and impact on healthcare. The company acquired PharmaLex, a global life sciences services provider, to enhance its specialty services and manufacturer capabilities. Cencora invested in OneOncology, a network of US oncology practices, to deepen relationships with community oncologists. Werner Baumann and Lauren Tyler were appointed as new independent directors to the Board in October 2023. The filing is a Definitive Proxy Statement (DEF 14A) filed on January 29, 2024, for the reporting period ending March 12, 2024.

Why It Matters

For investors and stakeholders tracking Cencora, Inc., this filing contains several important signals. The rebranding to Cencora signifies a strategic shift towards a unified global identity and a broader scope beyond traditional pharmaceutical distribution. Acquisitions of PharmaLex and OneOncology demonstrate Cencora's strategy to expand its specialized services and deepen relationships within the healthcare ecosystem, potentially driving future revenue growth and market share.

Risk Assessment

Risk Level: medium — Cencora, Inc. shows moderate risk based on this filing. The company is undergoing significant strategic changes including rebranding and acquisitions, which introduce integration risks and potential operational complexities that could impact financial performance.

Analyst Insight

Shareholders should review the proxy statement for details on executive compensation, board nominations, and strategic initiatives, particularly the integration plans for PharmaLex and OneOncology.

Key Numbers

Key Players & Entities

Forward-Looking Statements

FAQ

When did Cencora, Inc. file this DEF 14A?

Cencora, Inc. filed this Proxy Statement (DEF 14A) with the SEC on January 29, 2024.

What is a DEF 14A filing?

A DEF 14A is a definitive proxy statement sent to shareholders before annual meetings, covering executive compensation, board nominations, and shareholder votes. This particular DEF 14A was filed by Cencora, Inc. (COR).

Where can I read the original DEF 14A filing from Cencora, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Cencora, Inc..

What are the key takeaways from Cencora, Inc.'s DEF 14A?

Cencora, Inc. filed this DEF 14A on January 29, 2024. Key takeaways: Cencora, formerly AmerisourceBergen, rebranded in fiscal 2023 to reflect its global evolution and impact on healthcare.. The company acquired PharmaLex, a global life sciences services provider, to enhance its specialty services and manufacturer capabilities.. Cencora invested in OneOncology, a network of US oncology practices, to deepen relationships with community oncologists..

Is Cencora, Inc. a risky investment based on this filing?

Based on this DEF 14A, Cencora, Inc. presents a moderate-risk profile. The company is undergoing significant strategic changes including rebranding and acquisitions, which introduce integration risks and potential operational complexities that could impact financial performance.

What should investors do after reading Cencora, Inc.'s DEF 14A?

Shareholders should review the proxy statement for details on executive compensation, board nominations, and strategic initiatives, particularly the integration plans for PharmaLex and OneOncology. The overall sentiment from this filing is neutral.

Risk Factors

Key Dates

Glossary

DEF 14A
Definitive Proxy Statement filed with the SEC. (Indicates the company is seeking shareholder votes on matters such as director elections and executive compensation.)
Fiscal 2023
The company's fiscal year ending in 2023. (Context for the strategic initiatives and rebranding mentioned in the filing.)

Filing Stats: 4,296 words · 17 min read · ~14 pages · Grade level 15.4 · Accepted 2024-01-29 16:31:40

Key Financial Figures

Filing Documents

: Election of directors

Item 1: Election of directors 10 Our Board of Directors 11 Corporate governance 21 Director compensation 36 Overview 36 Fiscal 2023 director compensation 38

Executive compensation

Executive compensation 39

: Advisory vote to approve the compensation of our named executive officers

Item 2: Advisory vote to approve the compensation of our named executive officers 39 Compensation discussion and analysis 40 Report of the Compensation Committee 61

Executive compensation tables

Executive compensation tables 62 CEO pay ratio 75 Pay versus performance 75 Audit matters 81 Item 3: Ratification of the appointment of Ernst & Young LLP as Cencora's Independent Registered Public Accounting Firm for Fiscal 2024 81 Selection and engagement of audit firm 82 Audit and non-audit fees 82 Pre-approval policies 82 Report of the Audit Committee 83 Item 4: Approval of an amendment of the certificate of incorporation to provide for the exculpation of officers as permitted by Delaware law 84

: Approval of miscellaneous amendments to the certificate of incorporation

Item 5: Approval of miscellaneous amendments to the certificate of incorporation 86

: Shareholder proposal

Item 6: Shareholder proposal 88 Stock ownership information 91

Security ownership of certain beneficial owners, officers and directors

Security ownership of certain beneficial owners, officers and directors 91 Equity compensation plan information 93 Delinquent Section 16(a) reports 93 Frequently asked questions about the 2024 Annual Meeting of Shareholders and voting at the meeting 94 Other Information 99 Availability of the Annual Report on Form 10-K 99 Requirements for submission of proxy proposals, nomination of directors and other business of shareholders 99 Appendix A A-1 Supplemental information: GAAP to non-GAAP reconciliation A-1 Exhibits A-1 Exhibit A: Proposed amended and restated certificate of incorporation A-1 Exhibit B: Proposed changes to current amended and restated certificate of incorporation (marked to show changes) B-1 Cautionary note regarding forward-looking statements Certain of the statements contained in this proxy statement and elsewhere in this report are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as "aim," "anticipate," "believe," "can," "continue," "could," "estimate," "expect," "intend," "may," "might," "on track," "opportunity," "plan," "possible," "potential," "predict," "project," "seek," "should," "strive," "sustain," "synergy," "target," "will," "would" and similar expressions are intended to identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances and speak only as of the date hereof. These statements are not guarantees of future performance and are based on assumptions and estimates that could prove incorrect or could cause actual results to vary materially from those indicated. Websites Website addresses referenced in this proxy statement are intended to be inactive textual r

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on Read The Filing